MA39170A1 - Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer - Google Patents

Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer

Info

Publication number
MA39170A1
MA39170A1 MA39170A MA39170A MA39170A1 MA 39170 A1 MA39170 A1 MA 39170A1 MA 39170 A MA39170 A MA 39170A MA 39170 A MA39170 A MA 39170A MA 39170 A1 MA39170 A1 MA 39170A1
Authority
MA
Morocco
Prior art keywords
serine
cancer
treatment
threonine kinase
inhibitory compounds
Prior art date
Application number
MA39170A
Other languages
English (en)
Other versions
MA39170B1 (fr
Inventor
Aleksandr Kolesnikov
Steven Do
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA39170A1 publication Critical patent/MA39170A1/fr
Publication of MA39170B1 publication Critical patent/MA39170B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne des composés de formule (i) dans laquelle r1, x1, x2, x3 et x4 sont, tels que définis dans le présent document, des inhibiteurs de la protéine erk. L'invention concerne également des compositions et des procédés de traitement de troubles hyperprolifératifs.
MA39170A 2013-12-06 2014-12-03 Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer MA39170B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912905P 2013-12-06 2013-12-06
PCT/US2014/068452 WO2015085007A1 (fr) 2013-12-06 2014-12-03 Inhibiteurs de sérine/thréonine kinase

Publications (2)

Publication Number Publication Date
MA39170A1 true MA39170A1 (fr) 2018-04-30
MA39170B1 MA39170B1 (fr) 2019-05-31

Family

ID=52350292

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39170A MA39170B1 (fr) 2013-12-06 2014-12-03 Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer

Country Status (23)

Country Link
US (5) US9867833B2 (fr)
EP (1) EP3077401B1 (fr)
JP (2) JP6449293B2 (fr)
KR (1) KR102359759B1 (fr)
CN (1) CN106029672B (fr)
AR (1) AR098647A1 (fr)
AU (1) AU2014360455B2 (fr)
BR (1) BR112016012844B1 (fr)
CA (1) CA2932729C (fr)
CL (1) CL2016001368A1 (fr)
CR (1) CR20160309A (fr)
EA (1) EA031243B1 (fr)
IL (1) IL246017B (fr)
MA (1) MA39170B1 (fr)
MX (1) MX368443B (fr)
MY (1) MY176049A (fr)
PE (1) PE20160886A1 (fr)
PH (1) PH12016501071A1 (fr)
SG (1) SG11201604573WA (fr)
TW (1) TWI557126B (fr)
UA (1) UA120506C2 (fr)
WO (1) WO2015085007A1 (fr)
ZA (1) ZA201604461B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007214A8 (pt) 2012-10-16 2018-02-06 Hoffmann La Roche composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015085007A1 (fr) 2013-12-06 2015-06-11 Genentech, Inc. Inhibiteurs de sérine/thréonine kinase
WO2015103133A1 (fr) 2013-12-30 2015-07-09 Genentech, Inc. Inhibiteurs de sérine/thréonine kinases
WO2015103137A1 (fr) 2013-12-30 2015-07-09 Array Biopharma Inc. Inhibiteurs de sérine/thréonine kinases
SG11201803066VA (en) * 2015-11-09 2018-05-30 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018012471A (es) 2016-04-15 2019-02-21 Genentech Inc Metodos de diagnostico y terapeuticos para el cancer.
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2019158579A1 (fr) 2018-02-13 2019-08-22 Vib Vzw Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr
JP7433898B2 (ja) 2019-12-26 2024-02-20 キヤノン株式会社 光電変換素子、光電変換システム

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464561A1 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Traitement utilisant une dose posologique de losartan a retention gastrique
US7579468B2 (en) 2005-09-15 2009-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
CN101679409B (zh) * 2006-12-22 2014-11-26 Astex治疗学有限公司 双环杂环衍生化合物、其医药组合物和其用途
EP2002836B1 (fr) * 2007-05-31 2010-10-20 Nerviano Medical Sciences S.r.l. Azaindoles cyclocondensés actifs en tant qu'inhibiteurs de la kinase
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
ES2857649T3 (es) * 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
KR20150047597A (ko) 2012-08-27 2015-05-04 어레이 바이오파마 인크. 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제
BR112015007214A8 (pt) 2012-10-16 2018-02-06 Hoffmann La Roche composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015085007A1 (fr) 2013-12-06 2015-06-11 Genentech, Inc. Inhibiteurs de sérine/thréonine kinase
WO2015103133A1 (fr) 2013-12-30 2015-07-09 Genentech, Inc. Inhibiteurs de sérine/thréonine kinases
WO2015103137A1 (fr) 2013-12-30 2015-07-09 Array Biopharma Inc. Inhibiteurs de sérine/thréonine kinases
CN106659721B (zh) 2014-04-09 2021-01-01 基因泰克公司 用于制备药物的方法

Also Published As

Publication number Publication date
MA39170B1 (fr) 2019-05-31
US20200078371A1 (en) 2020-03-12
AU2014360455A1 (en) 2016-07-07
EP3077401B1 (fr) 2018-04-18
EP3077401A1 (fr) 2016-10-12
US10517878B2 (en) 2019-12-31
NZ721361A (en) 2021-07-30
AR098647A1 (es) 2016-06-01
JP6449293B2 (ja) 2019-01-09
JP2019034970A (ja) 2019-03-07
WO2015085007A1 (fr) 2015-06-11
BR112016012844A2 (fr) 2017-08-08
US10278975B2 (en) 2019-05-07
EA201691177A1 (ru) 2016-10-31
US20150182537A1 (en) 2015-07-02
IL246017B (en) 2019-10-31
PH12016501071B1 (en) 2016-07-25
PH12016501071A1 (en) 2016-07-25
TW201522338A (zh) 2015-06-16
CN106029672B (zh) 2019-03-29
CA2932729C (fr) 2021-02-23
US9867833B2 (en) 2018-01-16
US10842799B2 (en) 2020-11-24
US20210106593A1 (en) 2021-04-15
US20180000833A1 (en) 2018-01-04
UA120506C2 (uk) 2019-12-26
EA031243B1 (ru) 2018-12-28
SG11201604573WA (en) 2016-07-28
CR20160309A (es) 2016-08-25
MX2016007352A (es) 2016-09-08
CN106029672A (zh) 2016-10-12
JP2016539153A (ja) 2016-12-15
PE20160886A1 (es) 2016-09-14
CA2932729A1 (fr) 2015-06-11
IL246017A0 (en) 2016-08-02
TWI557126B (zh) 2016-11-11
AU2014360455B2 (en) 2018-05-10
MX368443B (es) 2019-10-02
CL2016001368A1 (es) 2016-12-09
US11376260B2 (en) 2022-07-05
MY176049A (en) 2020-07-22
KR102359759B1 (ko) 2022-02-09
BR112016012844B1 (pt) 2023-01-10
ZA201604461B (en) 2022-05-25
US20190192534A1 (en) 2019-06-27
KR20160093703A (ko) 2016-08-08

Similar Documents

Publication Publication Date Title
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201792529A1 (ru) Ингибиторы тирозинкиназы
IN2014KN02601A (fr)
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MA34797B1 (fr) Hétéroaryles et leurs utilisations
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA35895B1 (fr) Inhibiteurs d'iap
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
MA38925A1 (fr) Dérivés de phénylalanine substitués
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
EA201591180A1 (ru) Составы ингибитора lfa-1
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов